Article

Increased serum soluble-endoglin level and its clinical significance in antiphospholipid syndrome

  • Ji LI ,
  • Li ZHENG ,
  • Lian-jie SHI ,
  • Jing XU ,
  • Jian-long SHU ,
  • Xue-wu ZHANG
Expand
  • 1. Department of Rheumatology and Immunology, Peking University People’ s Hospital, Beijing 100044, China
    2. Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China
    3. Department of Rheumatology and Immunology, Guangxi International Zhuang Medical Hospital, Nanning 530011, China

Received date: 2018-07-10

  Online published: 2018-12-18

Abstract

Objective: To detect the serum levels of soluble endothelial glycoprotein endoglin (s-Eng) in patients with antiphospholipid syndrome(APS) and to evaluate the correlation between s-Eng levels and clinical features and laboratory parameters.Methods:The levels of serum s-Eng were measured by enzyme linked immunosorbent assay ( ELISA) in 139 patients with APS, 44 patients with SLE but no APS, 37 patients with primary Sjogren’s syndrome (pSS), 23 patients with Bechet’s disease (BD), 22 patients with systemic sclerosis (SSc) and 22 persistent anticardiolipin antibody (aCL) positive indivi-duals without SLE or APS(simply aCL positive group) and 87 health controls(HC) without any auto-immune diseases. These APS patients included 64 primary APS patients and 75 APS patients secondary to SLE.The correlation between the clinical data, laboratory parameters, and serum s-Eng levels were analyzed.Independent samples t test,paired t test,Chi-square Test, Mann-Whitney U test, Pearson’s χ 2 test were used for statistical analyses. Results:(1)The serum levels of s-Eng were significantly higher in the patients with APS whether primary or secondary to SLE than in the health controls and simply aCL positive group and the patients with other autoimmune diseases, including SLE, pSS, BD and SSc(P<0.001).There was no significant difference in the serum s-Eng levels between simply aCL positive group and health controls[(5.17±2.00) mg/L vs.(5.04±1.11) mg/L, P>0.05]. (2) The best cut-off value for the diagnosis of APS was no less than 8.37 mg/L as mean ± 3SD value, with the sensitivity at 0.772 and the specificity at 0.928. The Youden index was 0.700. These results indicated good validity of s-Eng as a diagnostic marker for APS. (3)The proportions of artery thrombosis and pathological pregnancy were higher in the group of s-Eng -positive APS patients than that in s-Eng -negative group(46/81 vs. 19/58,29/65 vs. 10/44,respectively, all P<0.05).The levels of PLT were lower in the group of s-Eng-positive APS patients (72.00×10 9/L vs. 119.00×10 9/L, P<0.001). (4)The proportions of the presence(93.83% vs. 37.93%, P<0.001) and titer (61.70 U/mL vs.15.45 U/mL, P<0.001) of aCL were both higher in the group of s-Eng-positive APS patients than in s-Eng-negative group. The proportions of the presence (61.73% vs. 43.10%, P<0.05)and titer (33.48 U/mL vs.17.40 U/mL,P<0.05) of anti-β2-glycoproteinⅠ antibody were both higher in the group of s-Eng -positive APS patients than in s-Eng -negative group too. Conclusion:S-Eng serum levels were significantly increased in the patients with APS, and it may play a role as acomplementary serological marker for the diagnosis and risk prediction of APS.

Cite this article

Ji LI , Li ZHENG , Lian-jie SHI , Jing XU , Jian-long SHU , Xue-wu ZHANG . Increased serum soluble-endoglin level and its clinical significance in antiphospholipid syndrome[J]. Journal of Peking University(Health Sciences), 2018 , 50(6) : 1027 -1032 . DOI: 10.19723/j.issn.1671-167X.2018.06.015

References

[1] Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006,4(2):295-306.
[2] Pierangeli SS, Colden-Stanfield M, Liu X , et al. Antiphospholi-pid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo[J]. Circulation, 1999,99(15):1997-2002.
[3] Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B , et al. NFκB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein 1 antibodies[J]. Thromb Haemost, 2002,88(5):851-857.
[4] Charakida M, Besler C, Batuca JR , et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome[J]. JAMA, 2009,302(11):1210-1217.
[5] Ames PR, Batuca JR, Ciampa A , et al. Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome[J]. J Rheumatol, 2010,37(12):2523-2530.
[6] Ramesh S, Morrell CN, Tarango C , et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2[J]. J Clin Invest, 2011,121(1):120-131.
[7] Toporsian M, Gros R, Kabir MG , et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia[J]. Circ Res, 2005,96(6):684-692.
[8] Alt A, Miguel-Romero L, Donderis J , et al. Structural and functional insights into endoglin ligand recognition and binding[J]. PLoS One, 2012,7(2):e29948.
[9] Bernabeu C, Conley BA, Vary CP . Novel biochemical pathways of endoglin in vascular cell physiology[J]. J Cell Biochem, 2007,102(6):1375-1388.
[10] Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA , et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients[J]. BMC Med, 2010,8:86.
[11] Strasky Z, Vecerova L, Rathouska J , et al. Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice[J]. Circ J, 2011,75(7):1747-1755.
[12] Vitverova B, Blazickova K, Najmanova I , et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta[J]. Atherosclerosis, 2018,271:15-25.
[13] Emeksiz HC, Bideci A, Damar ? , et al. Soluble endoglin level increase occurs prior to development of subclinical structural vascular alterations in diabetic adolescents[J]. J Clin Res Pediatr Endocrinol, 2016,8(3):313-320.
[14] Rathouska J, Jezkova K, Nemeckova I , et al. Soluble endoglin, hypercholesterolemia and endothelial dysfunction[J]. Atherosclerosis, 2015,243(2):383-388.
[15] Bassyouni IH, El-Shazly R, Azkalany GS , et al. Clinical significance of soluble-endoglin levels in systemic lupus erythematosus: possible association with anti-phospholipid syndrome[J]. Lupus, 2012,21(14):1565-1570.
[16] Barbara NP, Wrana JL, Letarte M . Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily[J]. J Biol Chem, 1999,274(2):584-594.
[17] Kapur NK, Wilson S, Yunis AA , et al. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure[J]. Circulation, 2012,125(22):2728-2738.
[18] Venkatesha S, Toporsian M, Lam C , et al. Soluble endoglin contributes to the pathogenesis of preeclampsia[J]. Nat Med, 2006,12(6):642-649.
[19] Chatterjee A, Black SM, Catravas JD . Endothelial nitric oxide (NO) and its pathophysiologic regulation[J]. Vascul Pharmacol, 2008,49(4/5/6):134-140.
[20] Palmer RM, Ferrige AG, Moncada S . Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor[J]. Nature, 1987,327(6122):524-526.
[21] de Caterina R, Libby P, Peng HB , et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines[J]. J Clin Invest, 1995,96(1):60-68.
[22] Radomski MW, Palmer RM, Moncada S . Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium[J]. Lancet, 1987,2(8567):1057-1058.
[23] Lauer T, Preik M, Rassaf T , et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action[J]. Proc Natl Acad Sci USA, 2001,98(22):12814-12819.
[24] Robak E, Kierstan M, Cebula B , et al. Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus[J]. Lupus, 2009,18(4):332-341.
[25] Cervera R, Serrano R, Pons-Estel GJ , et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients[J]. Ann Rheum Dis, 2015,74(6):1011-1018.
[26] Derksen RH, de Groot PG . The obstetric antiphospholipid syndrome[J]. J Reprod Immunol, 2008,77(1):41-50.
[27] Holers VM, Girardi G, Mo L , et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss[J]. J Exp Med, 2002,195(2):211-220.
[28] Soh MC, Pasupathy D, Gray G , et al. Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes[J]. Rheumatology(Oxford), 2013,52(9):1642-1647.
[29] Levine RJ, Lam C, Qian C , et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia[J]. N Eng J Med, 2006,355(10):992-1005.
Outlines

/